PriceTargets.com logo

Celadon Pharmaceuticals - CEL Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 210
  • Forecasted Upside: 296.23%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 53 As of 01/27/2023 01:00 AM ET
+0 (0.00%)

This chart shows the closing price for CEL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Celadon Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CEL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CEL

Analyst Price Target is GBX 210
▲ +296.23% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Celadon Pharmaceuticals in the last 3 months. The average price target is GBX 210, with a high forecast of GBX 210 and a low forecast of GBX 210. The average price target represents a 296.23% upside from the last price of GBX 53.

This chart shows the closing price for CEL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Celadon Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/2/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/31/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/30/2022Canaccord Genuity GroupInitiated CoverageSpeculative BuyGBX 210
(Data available from 1/29/2018 forward)

News Sentiment Rating

0.30 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/2/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Celadon Pharmaceuticals logo
Celadon Pharmaceuticals Plc, a pharmaceutical company, engages in the research, manufacture, and supply of cannabinoids for use in approved medicines. The company focuses on growing indoor hydroponic THC cannabis for use in medicinal products used to treat chronic pain. It also intends to conduct research into cannabinoids for use in chronic pain, as well as other conditions, such as autism and multiple sclerosis. The company was founded in 2018 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 53
Low: 52
High: 54

50 Day Range

MA: GBX 52.46
Low: 47.50
High: 57

52 Week Range

Now: GBX 53
Low: 47.50
High: 160

Volume

39,153 shs

Average Volume

136,862 shs

Market Capitalization

£32.69 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Celadon Pharmaceuticals?

The following Wall Street sell-side analysts have issued stock ratings on Celadon Pharmaceuticals in the last twelve months: Canaccord Genuity Group Inc..
View the latest analyst ratings for CEL.

What is the current price target for Celadon Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Celadon Pharmaceuticals in the last year. Their average twelve-month price target is GBX 210, suggesting a possible upside of 296.2%. Canaccord Genuity Group Inc. has the highest price target set, predicting CEL will reach GBX 210 in the next twelve months. Canaccord Genuity Group Inc. has the lowest price target set, forecasting a price of GBX 210 for Celadon Pharmaceuticals in the next year.
View the latest price targets for CEL.

What is the current consensus analyst rating for Celadon Pharmaceuticals?

Celadon Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CEL will outperform the market and that investors should add to their positions of Celadon Pharmaceuticals.
View the latest ratings for CEL.

What other companies compete with Celadon Pharmaceuticals?

Other companies that are similar to Celadon Pharmaceuticals include Science in Sport, Diurnal Group, Venture Life Group, Shield Therapeutics and Evgen Pharma. Learn More about companies similar to Celadon Pharmaceuticals.

How do I contact Celadon Pharmaceuticals' investor relations team?

The company's listed phone number is 44 20 3150 0252. The official website for Celadon Pharmaceuticals is www.celadonpharma.co.uk. Learn More about contacing Celadon Pharmaceuticals investor relations.